Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $11.0 million.

  • Autolus Therapeutics' Accounts Payables rose 67341.33% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 67341.33%. This contributed to the annual value of $2.0 million for FY2024, which is 181165.05% up from last year.
  • Autolus Therapeutics' Accounts Payables amounted to $11.0 million in Q3 2025, which was up 67341.33% from $5.4 million recorded in Q2 2025.
  • Autolus Therapeutics' Accounts Payables' 5-year high stood at $11.0 million during Q3 2025, with a 5-year trough of -$1.3 million in Q2 2021.
  • For the 5-year period, Autolus Therapeutics' Accounts Payables averaged around $1.7 million, with its median value being $531000.0 (2022).
  • In the last 5 years, Autolus Therapeutics' Accounts Payables crashed by 30543.13% in 2021 and then skyrocketed by 195507.25% in 2024.
  • Autolus Therapeutics' Accounts Payables (Quarter) stood at $431000.0 in 2021, then increased by 23.2% to $531000.0 in 2022, then plummeted by 80.6% to $103000.0 in 2023, then surged by 1811.65% to $2.0 million in 2024, then skyrocketed by 456.98% to $11.0 million in 2025.
  • Its Accounts Payables was $11.0 million in Q3 2025, compared to $5.4 million in Q2 2025 and $4.5 million in Q1 2025.